Predictability of hematopoietic stem cell transplantation rates

Gratwohl, Aloïs; Baldomero, Helen; Schwendener, Alvin; Gratwohl, Michael; Apperley, Jane F.; Niederwieser, Dietger; Frauendorfer, Karl

doi:10.3324/haematol.11260

Cited by 38 publications

(45 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The factors for these differences were shown here and in a previous report. 5,7 Economic factors of the country, its strength as measured by GNI per capita or HCE per capita and the number of teams compared with its inhabitants and with its size correlate with transplant rates. This correlation is clear but with an s-shaped form and with a broad variation.…”

Section: Discussionmentioning

confidence: 99%

Why are there regional differences in stem cell transplantation activity? An EBMT analysis

Gratwohl

Baldomero

Frauendorfer

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

Differences in the number of hematopoietic SCTs (HSCT), in transplant rates, in indications and in techniques between countries have been reported. They were attributed mainly to differences in the economic situation of the countries or to differences in prevalences of the disease. On the basis of the results of the annual activity survey on HSCT of the European Blood and Marrow Transplantation (EBMT), we have analyzed the factors associated with differences between more than 600 teams participating from more than 40 countries over a time span of 15 years. The results show a more complex situation. The gross national income per capita, number of transplant teams per 10 million inhabitants or per 10 000 km 2 , team size and team experience all impact on transplant activity. Furthermore, hitherto unknown factors must add to the decisions to perform or not to perform HSCT. These data illustrate that more research is needed to understand the mechanism of HSCT activity and to enable health-care agencies to provide the necessary infrastructure.

show abstract

Section: Discussionmentioning

confidence: 99%

Why are there regional differences in stem cell transplantation activity? An EBMT analysis

Gratwohl

Baldomero

Frauendorfer

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…1 HSCT is still associated with significant morbidity and mortality for the patients. These risks are well defined.…”

Section: Introductionmentioning

confidence: 99%

Severe events in donors after allogeneic hematopoietic stem cell donation

Halter

Kodera²,

Ispizua³

et al. 2009

Haematologica

Self Cite

196

154

View full text Add to dashboard Cite

The online version of this article contains a supplementary appendix. BackgroundThe risk for donors of allogeneic hematopoietic stem cells transplants is generally considered negligible. Scattered reports of severe complications and a recent controversy on hematopoietic malignancies after granulocyte colony-stimulating factor administration have challenged this opinion. Design and MethodsThree hundred and thirty-eight allogeneic transplant teams from 35 primarily European countries were asked to report numbers of fatalities, severe adverse events and hematologic malignancies occurring among their hematopoietic stem cell donors. ResultsTwo hundred and sixty-two of the 338 teams (77.5%) responded to a first survey (1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000)(2001)(2002) and 169 of the 262 responder teams (65%) to a second survey (2003)(2004)(2005). They had performed a total of 51,024 first allogeneic hematopoietic stem cell transplantations, of which 27,770 were bone marrow and 23,254 peripheral blood. They observed five donor fatalities, one after a bone marrow donation and four after peripheral blood donation (incidence 0.98 per 10,000 donations; 95% CI 0.32-2.29), 37 severe adverse events (7.25/10,000; 95% CI 5.11-9.99), of which 12 in bone marrow donors (4.32/10,000; 95% CI 2.24-7.75) and 25 in peripheral blood donors (10.76/10,000; 95% CI 6.97-15.85; p<0.05) and 20 hematologic malignancies (3.92/10,000; 95% CI 2.39-6.05), of which 8 after donating bone marrow and 12 after donating peripheral blood stem cells. The observed incidence rate of hematologic malignancies did not exceed the expected incidence in an age-and sex-adjusted general population. ConclusionsHematopoietic stem cell donation is associated with a small but definite risk of fatalities and serious adverse events. True incidences might be higher, due to potential underreporting by study design. A continuous, standardized donor follow-up is needed to define donor risk groups and to monitor intermediate and long-term sequelae.Key words: hematopoietic stem cell donation, adverse event, hematologic malignancies, donor fatality. Haematologica 2009; 94:94-101. doi: 10.3324/haematol.13668 ©2009 Ferrata Storti Foundation. This is an open-access paper. Citation: Halter J, Kodera Y, Urbano Ispizua A, Greinix HT, Schmitz N, Favre G, Baldomero H, Niederwieser D, Apperley JF, and Gratwohl A, for the European Group for Blood and Marrow Transplantation (EBMT) activity survey office. Severe events in donors after allogeneic hematopoietic stem cell donation. Severe events in donors after allogeneic hematopoietic stem cell donation

show abstract

“…This long array of mobilizing agents has been used, clinically and experimentally in animal models, to induce HSC mobilization 21 and transplantation of PB containing a high number of mobilized HSC has become a standard in the treatment of many disorders. [22][23][24] Currently the most promising mobilizing agent is the bicyclam molecule AMD3100 which specifically and reversibly blocks SDF-1 binding to CXCR4 and induces rapid mobilization of mouse and human HSPC.…”

Section: Introductionmentioning

confidence: 99%

Heparan sulfate mimetics can efficiently mobilize long-term hematopoietic stem cells

Giacomo

Lewandowski²,

Cabannes³

et al. 2011

Haematologica

View full text Add to dashboard Cite

The online version of this article has a Supplementary Appendix. BackgroundAlthough mobilization of hematopoietic stem cells and hematopoietic progenitor cells can be achieved with a combination of granulocyte colony-stimulating factor and plerixafor (AMD3100), improving approaches for hematopoietic progenitor cell mobilization is clinically important. Design and MethodsHeparan sulfate proteoglycans are ubiquitous macromolecules associated with the extracellular matrix that regulates biology of hematopoietic stem cells. We studied the effects of a new family of synthetic oligosaccharides mimicking heparan sulfate on hematopoietic stem cell mobilization. These oligosaccharides were administered intravenously alone or in combination with granulocyte colony-stimulating factor and/or AMD3100 in mice. Mobilized hematopoietic cells were counted and phenotyped at different times and the ability of mobilized hematopoietic stem cells to reconstitute long-term hematopoiesis was determined by competitive transplantation into syngenic lethally irradiated mice followed by secondary transplantation. ResultsMimetics of heparan sulfate induced rapid mobilization of B-lymphocytes, T-lymphocytes, hematopoietic stem cells and hematopoietic progenitor cells. They increased the mobilization of hematopoietic stem cells and hematopoietic progenitor cells more than 3-fold when added to the granulocyte colony-stimulating factor/AMD3100 association. Hematopoietic stem cells mobilized by mimetics of heparan sulfate or by the granulocyte colony-stimulating factor/AMD3100/mimetics association were as effective as hematopoietic stem cells mobilized by the granulocyte colony-stimulating factor/AMD3100 association for primary and secondary hematopoietic reconstitution of lethally irradiated mice. ConclusionsThis new family of mobilizing agents could alone or in combination with granulocyte colonystimulating factor and/or AMD3100 mobilize a high number of hematopoietic stem cells that were able to maintain long-term hematopoiesis. These results strengthen the role of heparan sulfates in the retention of hematopoietic stem cells in bone marrow and support the use of small glyco-drugs based on heparan sulfate in combination with granulocyte colony-stimulating factor and AMD3100 to improve high stem cell mobilization, particularly in a prospect of use in human therapeutics.Key words: hematopoietic stem cell mobilization, heparan sulfate, hematopoietic reconstitution, VEGF, SDF-1α. Haematologica 2012;97(4):491-499. doi:10.3324/haematol.2011 Citation: Di Giacomo F, Lewandowski D, Cabannes E, Nancy-Portebois V, Petitou M, Fichelson S, and Romeo P-H. Heparan sulfate mimetics can efficiently mobilize long-term hematopoietic stem cells.

show abstract

Predictability of hematopoietic stem cell transplantation rates

Cited by 38 publications

References 30 publications

Why are there regional differences in stem cell transplantation activity? An EBMT analysis

Why are there regional differences in stem cell transplantation activity? An EBMT analysis

Severe events in donors after allogeneic hematopoietic stem cell donation

Heparan sulfate mimetics can efficiently mobilize long-term hematopoietic stem cells

Contact Info

Product

Resources

About